Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial-Reference-Cited by-同舟云学术

Dose Escalation for Prostate Adenocarcinoma: A Long-Term Update on the Outcomes of a Phase 3, Single Institution Randomized Clinical Trial

Published:2019-07 Issue:4 Volume:104 Page:790-797
ISSN:0360-3016
Container-title:International Journal of Radiation Oncology*Biology*Physics
language:en
Short-container-title:International Journal of Radiation Oncology*Biology*Physics

Author:

Pasalic Dario,Kuban Deborah A.,Allen Pamela K.,Tang Chad,Mesko Shane M.,Grant Stephen R.,Augustyn Alexander A.,Frank Steven J.,Choi Seungtaek,Hoffman Karen E.,Nguyen Quynh-Nhu,McGuire Sean E.,Pollack Alan,Anscher Mitchell S.

Funder

National Cancer Institute

U.S. Department of Health and Human Services

DOD

Varian Medical Systems

Publisher

Elsevier BV

Subject

Cancer Research,Radiology Nuclear Medicine and imaging,Oncology,Radiation

Reference28 articles.

1. Factors influencing prostate cancer patterns of care: An analysis of treatment variation using the SEER database;Burt;Adv Radiat Oncol,2018

2. Meta-analysis of the alpha/beta ratio for prostate cancer in the presence of an overall time factor: Bad news, good news, or no news?;Vogelius;Int J Radiat Oncol Biol Phys,2013